Dentsply Sirona to Present at the Stifel 2019 Dental & Veterinary Conference on May 29th
May 23 2019 - 8:30AM
DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), the Dental
Solutions Company, today announced that it will participate in the
Stifel 2019 Dental & Veterinary Conference on May 29th in New
York City.
Nick Alexos, CFO, will represent the company and is scheduled to
present at 3:00 PM ET. Investors and other interested parties
will be able to access a live audio webcast of the presentation by
visiting www.dentsplysirona.com.
In advance of the presentation, the Company today reaffirmed its
2019 financial guidance and reiterated its long-term financial
expectations.
A replay of the presentation will also be available on the
Dentsply Sirona website at www.dentsplysirona.com.
About Dentsply SironaDentsply
Sirona is the world’s largest manufacturer of professional dental
products and technologies, with a 132-year history of innovation
and service to the dental industry and patients worldwide.
Dentsply Sirona develops, manufactures, and markets a comprehensive
solutions offering including dental and oral health products as
well as other consumable medical devices under a strong portfolio
of world class brands. As The Dental Solutions Company,
Dentsply Sirona’s products provide innovative, high-quality and
effective solutions to advance patient care and deliver better,
safer and faster dentistry. The Company’s shares of common
stock are listed in the United States on Nasdaq under the symbol
XRAY. Visit www.dentsplysirona.com for more information about
Dentsply Sirona and its products.
Contact Information:
Investors:John Sweeney, CFA, IRCVice President,
Investor
Relations+1-717-849-7863John.Sweeney@dentsplysirona.com
Forward-Looking Statements and
Associated Risks
Information the Company has included or
incorporated by reference in this release, and information which
may be contained in other filings with the U. S. Securities and
Exchange Commission (the “SEC”) as well as press releases or other
public statements, contains or may contain forward-looking
statements. These forward-looking statements include, among
other things, statements about the completion of the year-end
financial statement audit and expected financial results referred
to herein, and/or statements about the Company’s plans, objectives,
expectations (financial or otherwise) or intentions, including the
Company's 2019 guidance.
The Company’s forward-looking statements involve
risks and uncertainties. Actual results may differ
significantly from those projected or suggested in any
forward-looking statements. The Company does not undertake
any obligation to release publicly any revisions to such
forward-looking statements to reflect events or circumstances
occurring after the date hereof or to reflect the occurrence of
unanticipated events. Any number of factors could cause the
Company’s actual results to differ materially from those
contemplated by any forward-looking statements, including, but not
limited to, the risks associated with the following:
- the preliminary nature of the financial results contained in
this release
- the Company's ability to successfully implement its cost
reduction and restructuring plans
- the Company’s ability to remain profitable in a very
competitive marketplace, which depends upon the Company’s ability
to differentiate its products and services from those of
competitors
- the Company’s failure to anticipate and appropriately adapt to
changes or trends within the rapidly changing dental
industry
- the effect of changes in the Company’s management and
personnel
- changes in applicable laws, rules or regulations, or their
interpretation or enforcement, or the enactment of new laws, rules
or regulations, which apply to the Company’s business practices
(past, present or future) or require the Company to spend
significant resources for compliance
- a significant failure or disruption in service within the
Company’s operations or the operations of key
distributors
- results in pending and future litigation, investigations or
other proceedings which could subject the Company to significant
monetary damages or penalties and/or require us to change our
business practices, or the costs incurred in connection with such
proceedings
- the Company’s failure to attract and retain talented employees,
or to manage succession and retention for its Chief Executive
Officer or other key executives
- the Company’s failure to successfully integrate the business
operations or achieve the anticipated benefits from any acquired
businesses
- the Company’s failure to execute on, or other issues arising
under, certain key client contracts
- the impact of the Company’s debt service obligations on the
availability of funds for other business purposes, the terms of and
required compliance with covenants relating to the Company’s
indebtedness and its access to the credit markets in
general
- general economic conditions
- other risks described from time to time in the Company’s
filings with the SEC
You should carefully consider these and other
relevant factors, including those risk factors in Part I, Item 1A,
“Risk Factors” in the Company's most recent Form 10-K and any other
information included or incorporated by reference in this Report,
and information which may be contained in the Company’s other
filings with the SEC, when reviewing any forward-looking
statement. Investors should understand it is impossible to
predict or identify all such factors or risks. As such, you
should not consider either foregoing lists, or the risks identified
in the Company’s SEC filings, to be a complete discussion of all
potential risks or uncertainties associated with an investment in
the Company.
DENTSPLY SIRONA (NASDAQ:XRAY)
Historical Stock Chart
From Mar 2024 to Apr 2024
DENTSPLY SIRONA (NASDAQ:XRAY)
Historical Stock Chart
From Apr 2023 to Apr 2024